3 Aug 2018 Jahr - FDA convened a joint meeting of the Anesthetic
and Analgesic Drug Products Advisory
Committee and the Drug Safety and Risk
Management Advisory Committee to discuss
results from assessments of the transmucosal
immediate-release fentanyl (TIRF) medicines’ risk
evaluation and mitigation strategy (REMS),
approved in December 2011. The TIRF REMS
requires that healthcare providers who
prescribe TIRF medicines for outpatient use are
specially certified, that pharmacies that dispense
TIRF medicines for i
Zugefügt zum Band der Zeit:
Opioids and the FDA
Datum:
